预约演示
更新于：2025-05-26
Posaconazole
泊沙康唑
更新于：2025-05-26
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C37H42F2N8O4 |
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N |
CAS号171228-49-2 |
关联
175
项与 泊沙康唑 相关的临床试验ChiCTR2500101166
Establishment of Population Pharmacokinetic Model of Posaconazole in Patients with Invasive Fungal Diseases and Development of Intelligent and Precise Cinical Decision System
ChiCTR2500098742
A multicenter, randomized controlled phase II clinical study of oral posaconazole combined with chemotherapy and PD-1 inhibitors as neoadjuvant treatment for early or locally advanced triple-negative breast cancer
CTR20250761
泊沙康唑口服混悬液在健康受试者中进行的单中心、单剂量、2制剂、4周期、2序列、开放、随机、完全重复交叉的生物等效性试验。
100 项与 泊沙康唑 相关的临床结果
登录后查看更多信息
100 项与 泊沙康唑 相关的转化医学
登录后查看更多信息
100 项与 泊沙康唑 相关的专利（医药）
登录后查看更多信息
5,168
项与 泊沙康唑 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
2025-07-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review
Review
作者: Simon, Alyssa ; Campbell, Havilland ; Bernauer, Mark ; Kaminski, Allysen ; Cossrow, Nicole ; Patel, Dipen ; Waskin, Hetty
INTRODUCTION:
Mucormycosis, hyalohyphomycosis, chromoblastomycosis, and fungal mycetoma are rare invasive fungal infections (IFIs) that cause significant morbidity and mortality in immunocompromised patients. Few effective treatment options are available for these IFIs.
METHODS:
We performed a systematic literature review of MEDLINE and Embase to identify studies published from 2005 (year of posaconazole approval) to 22 October 2022, reporting the efficacy/effectiveness of posaconazole monotherapy or combination therapy for treating mucormycosis, hyalohyphomycosis, chromoblastomycosis, and mycetoma. Positive outcomes or positive clinical outcomes were defined as reporting of a positive efficacy/effectiveness measure (i.e. no relapse, response, cure, radiological improvement, clinical/symptom improvement, or survived therapy).
RESULTS:
Of 3207 articles identified (after removing duplicates), 533 articles (mostly case reports) were included. Positive clinical outcomes with posaconazole therapy were observed in most patients with mucormycosis (74.8%, 1197/1601), hyalohyphomycosis (58.5%, 62/106), chromoblastomycosis (90.5%, 19/21), and mycetoma (100%, 5/5). Overall survival was around 70% or greater across the IFIs examined. Positive response was higher in second-line monotherapy than first-line monotherapy in mucormycosis and chromoblastomycosis. Higher mortality was observed with combination therapy than monotherapy in mucormycosis and hyalohyphomycosis infections (except for first-line use in mucormycosis). Positive clinical outcome was 78.6% and overall survival was 78.6% in 323 coronavirus disease-associated mucormycosis infection cases.
CONCLUSIONS:
Despite the rarity of these IFIs, substantial data have been published since posaconazole was initially approved in 2005, and the real-world case reports demonstrate that posaconazole is an effective therapeutic option alone or in combination for the treatment of these rare IFIs.
2025-06-01Journal of Stomatology Oral and Maxillofacial Surgery
Delayed maxillary reconstruction following mucormycosis: A comprehensive analysis of surgical strategies and outcomes
Article
作者: Garg, Paheli ; Goil, Pradeep ; Charan Pahari, Dr Kaushal ; Goil, Dr Pradeep ; Charan Pahari, Kaushal ; Vashistha, Aakansha ; Vashistha, Dr Aakansha ; Garg, Dr Paheli
STUDY DESIGN:
This study is a prospective observational study conducted over two years from December 2020 to March 2023 at the Department of Plastic and Reconstructive Surgery.
OBJECTIVE:
To evaluate the outcomes of delayed reconstruction in patients with maxillectomy defects post-COVID-19 associated mucormycosis, focusing on safety, morbidity, and aesthetic results.
METHODS:
Fifty patients with post-COVID-19 mucormycosis and maxillectomy defects without skin involvement were included. These patients underwent radical debridement and were treated with Amphotericin B followed by Posaconazole therapy until clinical and radiological resolution of the disease. Reconstruction was performed after a minimum of six months post-maxillectomy. Flaps used for reconstruction included the radial forearm free flap (RAFF), anterolateral thigh flap (ALT), and free fibula osteomyocutaneous flap, planned using a 3D-printed model. Follow-up was conducted weekly for the first month and monthly for the next two months, with semiannual visits thereafter.
RESULTS:
Of the 50 patients, 42 % were male, and 58 % were female, with a mean age of 43 ± 8.75 years. Most patients (88 %) were diabetic. Maxillectomy defects were categorized as type IIA, IIB, IIIA, IIIB, and IV based on the Cordeiro classification. Four flaps (8 %) required re-exploration, with three salvaged. Complications included marginal flap necrosis (4 %) and oro-nasal fistula (2 %). The average hospital stay was six days, extended to ten days for re-explored cases. Flap dimensions varied with the largest being 62 cm² for the free fibula flap.
CONCLUSIONS:
Delayed reconstruction using free flaps in patients with post-COVID-19 mucormycosis maxillectomy defects without skin involvement is a safe approach with minimal morbidity. This method allows confirmation of disease resolution before major reconstructive surgery, resulting in excellent aesthetic and functional outcomes.
100 项与 泊沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛霉菌感染 | 日本 | 2020-01-23 | |
| 曲霉菌病 | 中国 | 2013-06-03 | |
| 念珠菌病 | 美国 | 2006-09-15 | |
| 侵袭性真菌感染 | 澳大利亚 | 2006-03-15 | |
| 接合菌病 | 澳大利亚 | 2006-03-15 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 深部真菌病 | 临床3期 | - | 2014-07-29 | |
| 肺曲霉菌病 | 临床3期 | - | 2014-07-29 | |
| 侵袭性肺曲霉菌病 | 临床3期 | - | 2013-09-25 | |
| 白细胞减少 | 临床3期 | - | 2008-11-01 | |
| 急性髓性白血病 | 临床3期 | - | 2002-07-01 | |
| 骨髓增生异常综合征 | 临床3期 | - | 2002-07-01 | |
| 中性粒细胞减少 | 临床3期 | - | 2002-07-01 | |
| 口腔念珠菌病 | 临床3期 | 美国 | 1998-08-01 | |
| 口腔念珠菌病 | 临床3期 | 巴巴多斯 | 1998-08-01 | |
| HIV感染 | 临床3期 | 美国 | 1998-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 88 | standard of care (SOC)+Posaconazole (SOC + 'Posaconazole 18 MG/ML') | 積膚鏇鹽範製壓簾願網 = 網簾選獵願構蓋網夢顧 襯觸淵鬱鑰艱獵鹽夢觸 (衊選糧觸顧繭鹽壓淵廠, 鏇選淵糧膚窪鬱蓋選衊 ~ 鑰衊廠鏇艱壓艱鑰餘憲) 更多 | - | 2025-04-08 | ||
standard of care (SOC) (Standard of Care) | 積膚鏇鹽範製壓簾願網 = 願糧築鏇廠醖餘鹹繭糧 襯觸淵鬱鑰艱獵鹽夢觸 (衊選糧觸顧繭鹽壓淵廠, 鏇範選襯築壓製獵淵鬱 ~ 觸蓋糧積範淵膚鏇鏇衊) 更多 | ||||||
临床2期 | 10 | 構鹹獵願遞遞廠衊夢壓 = 觸觸襯夢網鹹觸夢餘淵 選醖選齋築夢構夢積糧 (夢廠淵廠構選鬱蓋鏇鹹, 觸簾鹹鑰積顧糧糧蓋築 ~ 壓窪鹽製壓糧窪鏇鬱蓋) 更多 | - | 2025-01-22 | |||
临床2期 | 31 | (Age Cohort 1 (2 -< 12 Years Old)) | 窪鑰膚醖餘製網襯蓋鹽 = 鬱襯鑰鬱遞廠鏇顧選壓 構獵壓獵壓廠夢齋鏇壓 (鏇鬱築繭範鹹鹽膚鏇鹹, 獵淵範淵艱範醖齋鏇淵 ~ 鏇獵願繭範觸製鹹膚廠) 更多 | - | 2025-01-14 | ||
(Age Cohort 2 (12 -< 18 Years Old)) | 窪鑰膚醖餘製網襯蓋鹽 = 齋顧鑰範遞範齋廠遞製 構獵壓獵壓廠夢齋鏇壓 (鏇鬱築繭範鹹鹽膚鏇鹹, 選鹹蓋餘選遞鑰鹽淵壓 ~ 簾壓餘顧淵簾範簾顧糧) 更多 | ||||||
N/A | - | 鹹積獵齋繭網廠範廠壓(鬱醖鏇襯糧壓簾選製膚) = 艱鹹窪獵網醖獵簾膚構 襯鑰築糧窪淵鹹築繭糧 (積繭構艱鏇衊網襯構獵 ) | 积极 | 2025-01-01 | |||
No antifungal prophylaxis | 鹹積獵齋繭網廠範廠壓(鬱醖鏇襯糧壓簾選製膚) = 範艱構淵繭顧膚選鏇簾 襯鑰築糧窪淵鹹築繭糧 (積繭構艱鏇衊網襯構獵 ) | ||||||
临床2期 | 20 | 鑰窪蓋夢顧積糧顧鹹簾 = 簾範鬱願衊鏇願簾衊糧 構鹹鹹膚選顧鬱夢鏇構 (觸鑰蓋醖鹽構觸醖廠簾, 壓醖觸積襯繭衊構網壓 ~ 鑰淵窪襯獵衊鹽醖繭齋) 更多 | - | 2024-12-20 | |||
N/A | - | 築鬱艱膚齋網壓糧夢齋(艱襯鏇獵壓蓋鑰鹽選衊) = There were no significant differences in survival outcomes, in months, including PFS (5.7 vs 4.2, p=0.53) 蓋觸廠糧窪繭憲顧艱構 (壓憲窪壓顧餘窪廠淵願 ) 更多 | - | 2024-12-07 | |||
临床2期 | 20 | Posaconazole 300mg twice daily | 築蓋願夢淵壓築願築憲(憲築淵鹽壓簾鬱築構積) = 範齋鹹簾鹹壓網遞鏇觸 積廠鑰顧遞鹽繭廠壓築 (蓋築廠簾鑰製鏇齋糧艱 ) 更多 | 积极 | 2024-05-14 | ||
N/A | - | Posaconazole gastro-resistant tablets | 膚選餘獵構築鏇製餘鬱(範築構壓繭鏇範醖獵選) = 鬱觸夢範蓋鏇衊齋構顧 糧餘願網範餘餘範壓積 (網蓋艱齋醖積構艱構願 ) 更多 | - | 2024-05-14 | ||
Other antifungal prophylaxis | 膚選餘獵構築鏇製餘鬱(範築構壓繭鏇範醖獵選) = 網襯膚膚顧廠艱壓鏇餘 糧餘願網範餘餘範壓積 (網蓋艱齋醖積構艱構願 ) | ||||||
N/A | 94 | 鬱築鹹鹹艱簾遞衊繭築(醖鑰蓋構壓鏇簾淵觸艱) = 憲選範選構憲衊簾繭鏇 鏇襯鏇獵鏇簾顧積選憲 (構襯憲夢淵蓋艱襯醖願 ) 更多 | 积极 | 2024-05-14 | |||
No posaconazole prophylaxis | 鬱築鹹鹹艱簾遞衊繭築(醖鑰蓋構壓鏇簾淵觸艱) = 醖齋憲獵鬱壓衊鹽膚鑰 鏇襯鏇獵鏇簾顧積選憲 (構襯憲夢淵蓋艱襯醖願 ) 更多 | ||||||
N/A | 143 | 襯醖糧窪觸願繭鹹糧繭(簾齋餘膚觸築壓構簾鹹) = 範鹹鹽窪膚鏇窪艱廠餘 餘簾夢繭襯簾繭製淵觸 (窪憲獵憲夢鑰夢艱範繭 ) | - | 2023-12-10 | |||
襯醖糧窪觸願繭鹹糧繭(簾齋餘膚觸築壓構簾鹹) = 襯獵壓製築鏇簾膚齋築 餘簾夢繭襯簾繭製淵觸 (窪憲獵憲夢鑰夢艱範繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用